Since MS patients showed an increase in the constitutive levels of HDAC3, we predicted that PBMC from MS patients will be more resistant to the inhibitory actions of TSA on HDAC and will be reflected in reduced levels of p53 in MS patients when compared to HC. The gene discussed is TP53; the disease is myeloid sarcoma.